CN109476624A - 钠-葡萄糖协同转运蛋白2抑制剂的晶型 - Google Patents

钠-葡萄糖协同转运蛋白2抑制剂的晶型 Download PDF

Info

Publication number
CN109476624A
CN109476624A CN201780032964.6A CN201780032964A CN109476624A CN 109476624 A CN109476624 A CN 109476624A CN 201780032964 A CN201780032964 A CN 201780032964A CN 109476624 A CN109476624 A CN 109476624A
Authority
CN
China
Prior art keywords
crystal form
proline
compound
formula
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780032964.6A
Other languages
English (en)
Other versions
CN109476624B (zh
Inventor
舒楚天
王振华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Huisheng Biopharmaceutical Co ltd
Beijing Huizhiheng Biological Technology Co Ltd
Original Assignee
Hainan Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hainan Xuanzhu Pharma Co Ltd filed Critical Hainan Xuanzhu Pharma Co Ltd
Publication of CN109476624A publication Critical patent/CN109476624A/zh
Application granted granted Critical
Publication of CN109476624B publication Critical patent/CN109476624B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

本发明公开了钠‑葡萄糖协同转运蛋白2抑制剂的L‑脯氨酸共结晶体的晶型、其制备方法、药物组合物及应用。具体地涉及钠‑葡萄糖协同转运蛋白2抑制剂的式(1)所示化合物(2S,3R,4R,5S,6R)‑2‑(3‑(4‑(((1R,3s,5S)‑二环[3.1.0]己烷‑3‑基)氧基)苄基)‑4‑氯苯基)‑6‑(羟甲基)四氢‑2H‑吡喃‑3,4,5‑三醇的L‑脯氨酸共结晶体的晶型、其制备方法、药物组合物和应用。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201780032964.6A 2016-05-28 2017-05-27 钠-葡萄糖协同转运蛋白2抑制剂的晶型 Active CN109476624B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610369705X 2016-05-28
CN201610369705 2016-05-28
PCT/CN2017/086269 WO2017206827A1 (zh) 2016-05-28 2017-05-27 钠-葡萄糖协同转运蛋白2抑制剂的晶型

Publications (2)

Publication Number Publication Date
CN109476624A true CN109476624A (zh) 2019-03-15
CN109476624B CN109476624B (zh) 2021-07-09

Family

ID=60479727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780032964.6A Active CN109476624B (zh) 2016-05-28 2017-05-27 钠-葡萄糖协同转运蛋白2抑制剂的晶型

Country Status (6)

Country Link
US (1) US10793588B2 (zh)
EP (1) EP3466940B1 (zh)
JP (1) JP6785523B2 (zh)
KR (1) KR102226465B1 (zh)
CN (1) CN109476624B (zh)
WO (1) WO2017206827A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045525B (zh) * 2021-05-31 2021-09-17 北京惠之衡生物科技有限公司 一种c-糖苷类衍生物的制备方法及其制剂
CN113336733B (zh) * 2021-05-31 2022-02-18 北京惠之衡生物科技有限公司 一种sglt-2抑制剂的l-脯氨酸共结晶体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801989A (zh) * 2007-07-26 2010-08-11 莱西肯医药有限公司 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物
EP2891654A1 (en) * 2014-01-03 2015-07-08 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
CN104761522A (zh) * 2014-01-03 2015-07-08 山东轩竹医药科技有限公司 光学纯的苄基-4-氯苯基的c-糖苷衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
AU2006289093A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
ES2599330T3 (es) 2008-08-22 2017-02-01 Theracos Sub, Llc Proceso para la preparación de inhibidores de SGLT2
US9562029B2 (en) 2011-06-25 2017-02-07 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US9315438B2 (en) * 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801989A (zh) * 2007-07-26 2010-08-11 莱西肯医药有限公司 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物
EP2891654A1 (en) * 2014-01-03 2015-07-08 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
CN104761522A (zh) * 2014-01-03 2015-07-08 山东轩竹医药科技有限公司 光学纯的苄基-4-氯苯基的c-糖苷衍生物

Also Published As

Publication number Publication date
KR102226465B1 (ko) 2021-03-11
KR20190014529A (ko) 2019-02-12
WO2017206827A1 (zh) 2017-12-07
EP3466940B1 (en) 2021-11-17
CN109476624B (zh) 2021-07-09
JP2019517575A (ja) 2019-06-24
US10793588B2 (en) 2020-10-06
US20200131216A1 (en) 2020-04-30
JP6785523B2 (ja) 2020-11-18
EP3466940A4 (en) 2020-03-11
EP3466940A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
JP2014532639A (ja) Ｓｇｌｔ２阻害剤の結晶および非結晶形態
MX2007011546A (es) Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv.
JP7071588B2 (ja) モルホリノキナゾリン系化合物の結晶形の結晶、その製造方法、使用および医薬品組成物
KR20120114174A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
CN106995397B (zh) R-氨磺必利药用盐、制备方法、晶型及其用途
CN109476624A (zh) 钠-葡萄糖协同转运蛋白2抑制剂的晶型
JP2023071922A (ja) ７ｈ－ピロロ［２，３－ｄ］ピリミジンｊａｋ－阻害剤
CN104230907A (zh) 晶体制备方法及其用途
WO2015158298A1 (zh) 晶体、制备方法及其用途
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
EP3551617B1 (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
WO2018133705A1 (zh) Gft-505的晶型及其制备方法和用途
WO2012147832A1 (ja) フェニルピロール誘導体の結晶
JP6965274B2 (ja) ナトリウム−グルコース結合輸送体阻害剤のアミン溶媒和物、その調製方法およびその適用
CN111166891B (zh) 甘露醇共晶辅料及其制备方法和用途
CA2983475C (en) Fumarate and crystals of pyridylamine compound
CN110655516B (zh) 一种抗凝血药物的晶型
WO2022067724A1 (zh) 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
WO2023025270A1 (zh) 一种吲哚类化合物的固体形式及其制备方法和用途
CN116396305A (zh) 一种稠环衍生物的晶型、其制备方法及其应用
CN108026043A (zh) 一种萘环化合物的晶型
CN117209480A (zh) 一种甲状腺激素β受体调节剂的晶型及其制备方法与应用
JP6921850B2 (ja) Ｄｐｐｉｖ阻害剤のマレイン酸塩の多形およびその製造方法
KR20130108487A (ko) 치환 페닐알칸산의 신규 결정 및 제조 방법
CN108602817A (zh) 二肽基肽酶-iv 抑制剂的苯甲酸盐的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 570105 Tianyi International Building, 85 Binhai Avenue, Longhua District, Haikou City, Hainan Province, 27th Floor

Applicant after: Xuanzhu (Hainan) Pharmaceutical Technology Co.,Ltd.

Address before: 570105 Tianyi International Building, 85 Binhai Avenue, Longhua District, Haikou City, Hainan Province, 27th Floor

Applicant before: Hainan Xuanzhu Pharma Co.,Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20191021

Address after: Room 510, building 2, yard 88, Kechuang 6th Street, economic and Technological Development Zone, Daxing District, Beijing

Applicant after: Xuanzhu (Beijing) Pharmaceutical Technology Co.,Ltd.

Address before: 570105 Tianyi International Building, 85 Binhai Avenue, Longhua District, Haikou City, Hainan Province, 27th Floor

Applicant before: Xuanzhu (Hainan) Pharmaceutical Technology Co.,Ltd.

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004033

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20200914

Address after: 135000 No. 666, Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province

Applicant after: Jilin Huisheng biopharmaceutical Co.,Ltd.

Applicant after: Beijing huizhiheng Biotechnology Co.,Ltd.

Address before: Room 510, building 2, yard 88, Kechuang 6th Street, economic and Technological Development Zone, Daxing District, Beijing

Applicant before: Xuanzhu (Beijing) Pharmaceutical Technology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 135007 No. 666, Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province

Patentee after: Jilin Huisheng Biopharmaceutical Co.,Ltd.

Patentee after: Beijing huizhiheng Biotechnology Co.,Ltd.

Address before: NO.666 Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province

Patentee before: Jilin Huisheng biopharmaceutical Co.,Ltd.

Patentee before: Beijing huizhiheng Biotechnology Co.,Ltd.

CP03 Change of name, title or address
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Crystal form of sodium glucose co transporter 2 inhibitor

Effective date of registration: 20231013

Granted publication date: 20210709

Pledgee: Jilin Bank Co.,Ltd. Tonghua Meihekou Branch

Pledgor: Jilin Huisheng Biopharmaceutical Co.,Ltd.

Registration number: Y2023220000102

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20210709

Pledgee: Jilin Bank Co.,Ltd. Tonghua Meihekou Branch

Pledgor: Jilin Huisheng Biopharmaceutical Co.,Ltd.

Registration number: Y2023220000102

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Crystal form of sodium glucose co transporter 2 inhibitor

Granted publication date: 20210709

Pledgee: Industrial and Commercial Bank of China Limited Meihekou Branch

Pledgor: Jilin Huisheng Biopharmaceutical Co.,Ltd.

Registration number: Y2024220000070